FIELD: pharmacology.
SUBSTANCE: antiplatelet agent based on a polysaccharide is an oligochitosan with a molecular weight of 5 kDa or 10 kDa and deacetylation degree of 85% obtained from crab chitosan by hydrolysis with a dry enzyme preparation of the culture liquid of the mycelial fungus Myceliophthora fergusii strain VKM F_3932D.
EFFECT: agent has a high antiplatelet activity.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOALKILDEOXY DERIVATIVE OF CELLULOSE, METHOD OF ITS PRODUCTION AND AGENT POSSESSING ANTIPLATELET ACTIVITY | 2018 |
|
RU2694342C1 |
| AGENT POSSESSING ANTIAGGREGANT ACTIVITY | 2019 |
|
RU2696583C1 |
| METHOD FOR PATIENT-SPECIFIC SELECTION OF ANTIPLATELET DRUGS FOR PATIENTS IN NEED THEREOF | 2012 |
|
RU2499261C1 |
| METHOD OF DETERMINING THROMBOCYTE RESISTANCE TO DOUBLE ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2019 |
|
RU2710272C1 |
| METHOD FOR STUDYING ANTI-AGGREGATION ACTION OF PREPARATIONS BY DETERMINING BLOOD PLATELET AGGREGATION IN VITRO | 2000 |
|
RU2188419C2 |
| AGENT EXHIBITING ANTIPLATELET AND ANTICOAGULANT ACTIVITY | 2014 |
|
RU2573379C1 |
| METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
| METHOD FOR DETERMINATION OF HIGH RESIDUAL PLATELET REACTIVITY IN PATIENTS WITH CHRONIC HEART FAILURE RECEIVING ANTIPLATELET THERAPY | 2021 |
|
RU2767132C1 |
| HYDROHALIDES OF 11-PHENOXYETHYL AND 11-BENZYL-SUBSTITUTED 2,3,4,5-TETRAHYDRO[1,3]DIAZEPINO[1,2-a] BENZIMIDAZOLE, HAVING ANTIAGGREGANT ACTIVITY | 2015 |
|
RU2582618C1 |
| METHOD FOR PRODUCING LOW-MOLECULAR CHITOSAN AND CHITOSAN OLIGOMERS | 2016 |
|
RU2627870C1 |
